Grifols in a massive sell-off - looking for opportunities
The chart is self-explanatory!
Price to earnings getting very low, company is solid and should see a bounce sooner or later at major support levels.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
59.31 M EUR
6.59 B EUR
291.12 M
About GRIFOLS S.A.
Sector
CEO
Nacho Abia
Headquarters
Barcelona
Website
Founded
1940
ISIN
ES0171996087
FIGI
BBG000KXQMX1
Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma for therapeutic use. The Hospital division offers non-biological pharmaceutical products and medical supplies for hospital pharmacy. The Diagnostic division provides clinical analysis and laboratory testing tools to laboratories, hospitals and blood banks. The Raw materials division includes sales of intermediate biological products, as well as manufacturing services to third parties. The Company operates production facilities in Spain, the United States, Mexico and Australia, among others. It controls numerous subsidiaries.
Buy $GRFS - NRPicks 22 AprGrifols, S.A. is engaged in the acquisition, manufacture, preparation and sale of therapeutic products, mainly plasma derivatives. The company operates through the bioscientific, hospital, diagnostic, biosupplies and other divisions.
Buy $GRFS - NRPicks 11 MarGrifols, S.A. engages in the acquisition, manufacture, preparation and sale of therapeutic products, principally plasma derivatives. The company operates through the Bioscience, Hospital, Diagnostics, Bio Supplies and Others segments.
Revenue TTM 5.6B
Net Income TTM 208M
EBITDA TTM 894M
EBITDA mar
Predicción GRF 28-12-2021Predicción para GRF en Corto. Recomendada por nuestro algoritmo de IA. El horizonte temporal de la recomendación es 5 días.
Are we at the bottom yet?Grifols stock has been heavely punished during 2021.
First the pandemic difficulted the plasma collection. We must take into account the stimulus checks and the unemployment benefits from the US goverment wich might have disuaded people from going to the plasma collection centers to get some extra
GRF is set for actionA nice triangle at the end of a long way down. Even though we did not face the ultimate action, the chances are the stage is set for upside. The best case is to see the short-lived break down but the solo break up is valid as well.
GRIFOLS: Throw-back becoming a reality?After surpassing Fib 0.5, it looks like the stock is heading towards 0.382 level (21.81). Right now the company is immersed in a share repurchase program since 12/03/2021 and it has already acquired 19.23% of its €125 million valued shares objective. Maybe the company's financial advisers are playin
GRIFOLS: Results day coming on Feb 26. Then to the moon?68.2% of GRIFOLS revenues come from the US and Canada. Covid19 cases there seem to be decreasing. The company is delaying more and more its deadline of results for the phase III of the inmunoglobulina antiCovid-19, now until spring 2021.
If GRLS results are positive or better than expected (speciall
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
GRFS5271380
Grifols Escrow Issuer SA 4.75% 15-OCT-2028Yield to maturity
6.54%
Maturity date
Oct 15, 2028
Explore more bonds
Frequently Asked Questions
The current price of GRF is 11.130 EUR — it has increased by 4.36% in the past 24 hours. Watch GRIFOLS S.A. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BME exchange GRIFOLS S.A. stocks are traded under the ticker GRF.
GRF stock has risen by 7.95% compared to the previous week, the month change is a 10.47% rise, over the last year GRIFOLS S.A. has showed a −8.24% decrease.
We've gathered analysts' opinions on GRIFOLS S.A. future price: according to them, GRF price has a max estimate of 27.00 EUR and a min estimate of 9.00 EUR. Watch GRF chart and read a more detailed GRIFOLS S.A. stock forecast: see what analysts think of GRIFOLS S.A. and suggest that you do with its stocks.
GRF stock is 6.39% volatile and has beta coefficient of 1.34. Track GRIFOLS S.A. stock price on the chart and check out the list of the most volatile stocks — is GRIFOLS S.A. there?
Today GRIFOLS S.A. has the market capitalization of 7.56 B, it has increased by 1.04% over the last week.
Yes, you can track GRIFOLS S.A. financials in yearly and quarterly reports right on TradingView.
GRIFOLS S.A. is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
GRF earnings for the last quarter are 0.23 EUR per share, whereas the estimation was 0.20 EUR resulting in a 13.99% surprise. The estimated earnings for the next quarter are 0.12 EUR per share. See more details about GRIFOLS S.A. earnings.
GRIFOLS S.A. revenue for the last quarter amounts to 1.79 B EUR, despite the estimated figure of 1.76 B EUR. In the next quarter, revenue is expected to reach 1.90 B EUR.
GRF net income for the last quarter is 51.69 M EUR, while the quarter before that showed 14.84 M EUR of net income which accounts for 248.30% change. Track more GRIFOLS S.A. financial stats to get the full picture.
GRIFOLS S.A. dividend yield was 0.00% in 2023, and payout ratio reached 0.00%. The year before the numbers were 0.00% and 0.00% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 10, 2024, the company has 23.74 K employees. See our rating of the largest employees — is GRIFOLS S.A. on this list?
Like other stocks, GRF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GRIFOLS S.A. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GRIFOLS S.A. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GRIFOLS S.A. stock shows the neutral signal. See more of GRIFOLS S.A. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.